Pulsenmore

Company Overview

Snapshot

Founded in October 2014 by Elazar Sonnenschein, Pulsenmore operates with 51–200 employees. The company has raised a total of $118.3M across six funding rounds from six investors. In June 2026, Pulsenmore announced a strategic partnership with Ouma Health to expand access to remote prenatal care across the United States.

Business overview

Pulsenmore develops a reliable, universally accessible home ultrasound device for remote care, enabling patients to self-scan by connecting their smartphone to a handheld ultrasound cradle. These scans are then automatically sent for remote clinical assessment by healthcare providers. The company's primary focus is on at-home prenatal ultrasound for remote assessment of fetal well-being, empowering women to manage their pregnancies in collaboration with healthcare providers. Pulsenmore operates within the Health Tech & Life Sciences sector, specifically targeting medical devices, digital healthcare, and patient remote monitoring, serving markets in Israel, the United States, and Europe.

Strategic signal

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound, pioneering a new era of prenatal care in the U.S. This authorization is a significant regulatory validation, opening up the substantial U.S. market for its innovative technology and signaling strong growth potential for investors in the remote healthcare and medical device sectors.

Company Intelligence Q&A

What was a key recent strategic partnership for Pulsenmore?

In June 2026, Pulsenmore announced a strategic partnership with Ouma Health to expand access to remote prenatal care across the United States. This collaboration aims to broaden the reach of Pulsenmore's home ultrasound technology.

When did Pulsenmore receive FDA authorization for its home-use prenatal ultrasound?

Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound in November 2025, enabling a new era of prenatal care in the U.S.

What significant funding event occurred in June 2026?

In June 2026, Pulsenmore announced the pricing of a $7.5 million private placement with a single healthcare-focused institutional investor.

When did Pulsenmore commence trading on Nasdaq?

Pulsenmore commenced trading on Nasdaq in January 2026, expanding its FDA-authorized home prenatal ultrasound devices in the U.S. market.

What new commercial engagement did Pulsenmore announce in February 2026?

In February 2026, Pulsenmore announced its first commercial engagement with a leading U.S.-based medical center, building U.S. momentum following its FDA clearance.